retatrutide trial sign up australia Eli Lilly's Phase 3 clinical studies investigating retatrutide, the "triple-G" agonist, have found that long-term use can achieve substantial weight loss. Read about the work via the link in the comments New clinical trial for type

2013;98:E66471

While Ozempic is generally well-tolerated, some patients may experience gastrointestinal issues such as nausea, vomiting, or diarrhea

Lilly is following this with retatrutide, a triple agonist, which has completed phase 2 trials for treating obesity and cardiovascular disease

The findings predict that Retatrutide may offer better benefits including appetite control, energy levels, and weight loss, with fewer side effects than the other similar medications due to its ability to target 3 hormones

GLP-1 receptor agonist prescription trends 2012-2023

Age and genetics: Baseline collagen quality plays a significant role